Send your comments and tips to whitecoat@globe.com
  Awards Beth Israel Deaconess Medical Ctr. Boston Medical Center Boston University Brigham and Women's Hospital Broad Institute Cambridge Health Alliance Caritas St. Elizabeth's Medical Ctr. Children's Hospital Boston Dana-Farber Cancer Institute Grants Harvard University Joslin Diabetes Center Lahey Clinic Mass. General Hospital Mass. Health Law McLean Hospital MIT New England Baptist Hospital Personnel Moves Public Health Research Short White Coat Tufts-New England Medical Center Tufts University UMass Memorial Medical Center University of Massachusetts VA Medical Centers    A Healthy Blog Running A Hospital Nature Network Boston SciBos - Corie Lok's blog Kevin, M.D. Blog, MD Nurse at small Dr. Gwenn Is In Healthy Children blog WBUR's CommonHealth Other Globe Blogs
Elizabeth Cooney is a health reporter for the Worcester Telegram &
Gazette.
Boston Globe Health and Science staff:
Scott Allen Alice Dembner Carey Goldberg Liz Kowalczyk Stephen Smith Colin Nickerson Beth Daley Karen Weintraub, Deputy Health and Science Editor, and Gideon Gil, Health and Science Editor. Short White Coat blogger Ishani Ganguli Short White Coat blogger Jennifer Srygley  Week of:
November 11
Week of:
November 4
Week of:
October 28
Week of:
October 21
Week of:
October 14
Week of:
October 7
|
« Insuring the uninsured | Main | Appeals judge will hear nursing med student's plea for more break time » Friday, September 21, 2007Today's Globe: no Caritas sale, drugs costs, biotech drug debate, 9/11 clinicsThe Archdiocese of Boston was unable for a second time to sell its troubled Caritas Christi Health Care, according to industry officials, jeopardizing the ability of New England's second largest hospital chain to offer top-flight medical care. As overall healthcare costs continue to rise sharply, prescription drugs have emerged as a surprising exception. The bill Congress is soon expected to pass giving regulators more authority over pharmaceutical companies is most significant to biotech drug makers and their would-be generic rivals because of what was left out. Generic drug makers such as Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals failed to persuade lawmakers to attach legislation that would allow them to market generic versions of biotech drugs produced by the likes of Amgen Inc. and Genentech Inc. Two free New York City health clinics devoted to the treatment of thousands of individuals made ill by toxic materials dispersed during the Sept. 11, 2001, terrorist attack on the World Trade Center opened yesterday. Posted by Elizabeth Cooney at 06:54 AM
|
